Imaging of glutamate neurotransmitter alterations in Alzheimer's disease

NMR in Biomedicine

Volumn 26, Issue 4, 2013, Pages 386-391

  Haris, Mohammad ^a   Nath, Kavindra ^b   Cai, Kejia ^a   Singh, Anup ^a   Crescenzi, Rachelle ^a   Kogan, Feliks ^a   Verma, Gaurav ^b   Reddy, Sanjana ^a   Hariharan, Hari ^a   Melhem, Elias R ^b   Reddy, Ravinder ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzheimer's disease; Brain; Chemical exchange saturation transfer imaging; Glutamate; MRI; MRS

Indexed keywords

ALZHEIMER'S DISEASE; CHEMICAL EXCHANGE SATURATION TRANSFER; GLUTAMATE; HIGH SPATIAL RESOLUTION; MRS; POSITIVE CORRELATIONS; SATURATION TRANSFER; WILD-TYPE CONTROLS;

BRAIN; DISEASE CONTROL; MAGNETIC RESONANCE IMAGING; NEUROPHYSIOLOGY;

DIAGNOSIS;

CREATINE; GLUTAMIC ACID; NEUROTRANSMITTER; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN MAPPING; BRAIN SLICE; CONCENTRATION (PARAMETERS); CONTRAST ENHANCEMENT; CONTROLLED STUDY; GLUTAMATE CHEMICAL EXCHANGE SATURATION TRANSFER; INVESTIGATIVE PROCEDURES; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REPRODUCIBILITY; TRANSGENIC MOUSE; WHITE MATTER; WILD TYPE; ANIMAL; BRAIN; HUMAN; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY;

MUS; MUS MUSCULUS;

ALZHEIMER DISEASE; ANIMALS; BRAIN; GLUTAMIC ACID; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICE, TRANSGENIC; NEUROTRANSMITTER AGENTS; REPRODUCIBILITY OF RESULTS;

EID: 84875055222     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.2875     Document Type: Article

References (29)

1. Francis PT. Glutamatergic systems in Alzheimer's disease. Int. J. Geriatr. Psychiatry 2003; 18(Suppl 1): S15-S21.
2. Francis PT, Sims NR, Procter AW, Bowen DM. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives. J. Neurochem. 1993; 60(5): 1589-1604.
3. Kantarci K, Reynolds G, Petersen RC, Boeve BF, Knopman DS, Edland SD, Smith GE, Ivnik RJ, Tangalos EG, Jack CR Jr. Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3T. Am. J. Neuroradiol. 2003; 24(5): 843-849.
4. Rupsingh R, Borrie M, Smith M, Wells JL, Bartha R. Reduced hippocampal glutamate in Alzheimer disease. Neurobiol. Aging 2011; 32(5): 802-810.
5. Hattori N, Abe K, Sakoda S, Sawada T. Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. Neuroreport 2002; 13(1): 183-186.
6. Antuono PG, Jones JL, Wang Y, Li SJ. Decreased glutamate+glutamine in Alzheimer's disease detected in vivo with (1)H-MRS at 0.5 T. Neurology 2001; 56(6): 737-742.
7. Marjanska M, Curran GL, Wengenack TM, Henry PG, Bliss RL, Poduslo JF, Jack CR Jr, Ugurbil K, Garwood M. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U.S.A. 2005; 102(33): 11 906-11 910.
8. 1H NMR study of the hippocampus and cerebellum. J. Gerontol. A Biol. Sci. Med. Sci. 1997; 52(2): B111-B117.
9. Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR Jr, Feldman HH, Bokde AL, Alexander GE, Scheltens P, Vellas B, Dubois B, Weiner M, Hampel H, North American Alzheimer's Disease Neuroimaging Initiative (ADNI). Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol. Aging 2012; 33(7): 1203-1214.
10. Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B. Biomarkers for Alzheimer's disease therapeutic trials. Prog. Neurobiol. 2010a; 95(4): 579-593.
11. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Discov. 2010b; 9(7): 560-574.
12. DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science 2003; 302(5646): 830-834.
13. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007; 3(3): 186-191.
14. Vemuri P, Jack CR Jr. Role of structural MRI in Alzheimer's disease. Alzheimers Res. Ther. 2010; 2(4): 23.
15. Querbes O, Aubry F, Pariente J, Lotterie JA, Demonet JF, Duret V, Puel M, Berry I, Fort JC, Celsis P. Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve. Brain 2009; 132(Pt 8): 2036-2047.
16. 11C-ABP688. J. Nucl. Med. 2007; 48(2): 247-252.
17. Cai K, Haris M, Singh A, Kogan F, Greenberg JH, Hariharan H, Detre JA, Reddy R. Magnetic resonance imaging of glutamate. Nat. Med. 2012; 18(2): 302-306.
18. Zhou J, Payen JF, Wilson DA, Traystman RJ, van Zijl PC. Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat. Med. 2003; 9(8): 1085-1090.
19. Jones CK, Schlosser MJ, van Zijl PC, Pomper MG, Golay X, Zhou J. Amide proton transfer imaging of human brain tumors at 3T. Magn. Reson. Med. 2006; 56(3): 585-592.
20. van Zijl PC, Jones CK, Ren J, Malloy CR, Sherry AD. MRI detection of glycogen in vivo by using chemical exchange saturation transfer imaging (glycoCEST). Proc. Natl. Acad. Sci. U.S.A. 2007; 104(11): 4359-4364.
21. Singh A, Haris M, Cai K, Kassey VB, Kogan F, Reddy D, Hariharan H, Reddy R. Chemical exchange saturation transfer magnetic resonance imaging of human knee cartilage at 3T and 7T. Magn. Reson. Med. 2012; 68(2): 588-594.
22. Haris M, Cai K, Singh A, Hariharan H, Reddy R. In vivo mapping of brain myo-inositol. Neuroimage 2011; 54(3): 2079-2085.
23. 1H spectra with LCModel. NMR Biomed. 2001; 14(4): 260-264.
24. Liu G, Gilad AA, Bulte JW, van Zijl PC, McMahon MT. High-throughput screening of chemical exchange saturation transfer MR contrast agents. Contrast Media Mol. Imaging, 2010; 5(3): 162-170.
25. Mu Y, Gage FH. Adult hippocampal neurogenesis and its role in Alzheimer's disease. Mol. Neurodegen. 2011; 6(1): 85.
26. Chen SQ, Wang PJ, Ten GJ, Zhan W, Li MH, Zang FC. Role of myo-inositol by magnetic resonance spectroscopy in early diagnosis of Alzheimer's disease in APP/PS1 transgenic mice. Dement. Geriatr. Cogn. Disord. 2009; 28(6): 558-566.
27. Ward KM, Balaban RS. Determination of pH using water protons and chemical exchange dependent saturation transfer (CEST). Magn. Reson. Med. 2000; 44(5): 799-802.
28. Winter PM, Cai K, Chen J, Adair CR, Kiefer GE, Athey PS, Gaffney PJ, Buff CE, Robertson JD, Caruthers SD, Wickline SA, Lanza GM. Targeted PARACEST nanoparticle contrast agent for the detection of fibrin. Magn. Reson. Med. 2006; 56(6): 1384-1388.
29. Sun PZ, Farrar CT, Sorensen AG. Correction for artifacts induced by B(0) and B(1) field inhomogeneities in pH-sensitive chemical exchange saturation transfer (CEST) imaging. Magn. Reson. Med. 2007; 58(6): 1207-1215.